• Innovent Biologics’ arcotatug tavetecan met overall survival and progression-free survival endpoints in the Phase 3 G-HOPE-001 trial.
• Median overall survival reached 10.2 months versus 6.9 months with physician’s-choice treatment.
• Median progression-free survival was 7.1 months versus 3.1 months with physician’s-choice treatment.
• China accepted the drug’s application, making it the first CLDN18.2 ADC under regulatory review globally; Japan filing is targeted for 2027.
• IBI354 combined with pertuzumab achieved a 95% response rate in 20 patients with HER2-positive breast cancer; no interstitial lung disease occurred.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief on October 26, 2026, and is solely responsible for the information contained therein.